All In Biotech

Drug Trial Radar · NCT05562362

Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension

A Three Way Sequential, Randomised, Open-Label Study Designed to Evaluate the Single and Multiple-Dose Pharmacokinetics and the Effect of Food on the Single-Dose Pharmacokinetics of Oral Sparsentan Suspension in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 30, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

47

Actual

Start

Jun 18, 2020

Primary completion

Nov 12, 2020

Study completion Nov 12, 2020

Sponsor

Lead sponsor
Travere Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This single-center, open-label, randomized, single and multiple-dose, 3-way sequential study at 3 dose levels will be performed in healthy subjects. Subjects will be randomized to 1 of the 3 dose levels. In each dose level, subjects will be administered a single dose in the fasted state and then a single dose in the fed state, followed by 14 days of dosing to assess Pharmacokinetics (PK) following multiple dosing.

Conditions

  • Healthy Subjects

Interventions

  • RE-021, sparsentanDrug

    RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of single-dose pharmacokinetics of sparsentan oral suspension dosed in fed and fasted states - CmaxTime frame: Study Days 1 and 8
  2. Assessment of single-dose pharmacokinetics of sparsentan oral suspension dosed in fed and fasted states - AUC(0-last)Time frame: Study Days 1 and 8
  3. Assessment of single-dose pharmacokinetics of sparsentan oral suspension dosed in fed and fasted - states - AUC(0-inf)Time frame: Study Days 1 and 8
  4. Food effect on pharmacokinetics of sparsentan oral suspension dosed after standard high-fat - breakfast - CmaxTime frame: Study Days 1 and 8
  5. Food effect on pharmacokinetics of sparsentan oral suspension dosed after standard high-fat - breakfast - AUC(0-last)Time frame: Study Days 1 and 8
  6. Food effect on pharmacokinetics of sparsentan oral suspension dosed after standard high-fat breakfast - AUC(0-inf)Time frame: Study Days 1 and 8
  7. Multiple-dose pharmacokinetics of a sparsentan oral suspension dosed in the fed state - CmaxTime frame: Study Days 12 to 28
  8. Multiple-dose pharmacokinetics of a sparsentan oral suspension dosed in the fed state - AUC(0-24)Time frame: Study Days 12 to 28
  9. Multiple-dose pharmacokinetics of a sparsentan oral suspension dosed in the fed state - TCP (AUC(0-24)/AUC(0-inf)Time frame: Study Days 12 to 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Travere Investigational Site

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.